Literature DB >> 20444934

Treatment of persistent or recurrent papillary carcinoma of the thyroid--the good, the bad, and the unknown.

Robert Udelsman.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20444934     DOI: 10.1210/jc.2010-0583

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


× No keyword cloud information.
  5 in total

1.  Upregulation of the signal transducers and activators of transcription 3 (STAT3) pathway in lymphatic metastases of papillary thyroid cancer.

Authors:  Jingdong Zhang; Anthony Gill; Bryn Atmore; Amber Johns; Leigh Delbridge; Raymond Lai; Todd McMullen
Journal:  Int J Clin Exp Pathol       Date:  2011-04-28

2.  Immunohistochemical Evaluation of β-Catenin Marker in Papillary Thyroid Cancer: Clinicopathologic Significance.

Authors:  Katayoun Ziari; Mojgan Sanjari; Moeinadin Safavi
Journal:  Iran J Pathol       Date:  2018-07-17

3.  Quality of Life in Papillary Thyroid Microcarcinoma Patients Undergoing Radiofrequency Ablation or Surgery: A Comparative Study.

Authors:  Yu Lan; Yukun Luo; Mingbo Zhang; Zhuang Jin; Jing Xiao; Lin Yan; Yaqiong Zhu
Journal:  Front Endocrinol (Lausanne)       Date:  2020-05-15       Impact factor: 5.555

4.  Quality of Life and Surgical Outcome of Transoral Endoscopic Thyroidectomy Vestibular Approach (TOETVA) versus Open Thyroid Surgery: Experience from a Single Center in Vietnam.

Authors:  Hau Xuan Nguyen; Hien Xuan Nguyen; Hoai Thi Hoang; Quang Van Le
Journal:  J Thyroid Res       Date:  2022-10-11

5.  Short-term Follow-up US Leads to Higher False-positive Results Without Detection of Structural Recurrences in PTMC.

Authors:  Jung Hyun Yoon; Hye Sun Lee; Eun-Kyung Kim; Ji Hyun Youk; Hyun Gi Kim; Hee Jung Moon; Jin Young Kwak
Journal:  Medicine (Baltimore)       Date:  2016-01       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.